Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome) Approved Drugs
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome).
Found 1 Approved Drug for Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome)
Aldurazyme
Generic Name
Laronidase
Aldurazyme
Generic Name
Laronidase
Form: Injection
Method of administration: Intravenous
FDA approval date: April 30, 2003
Classification: Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme
ALDURAZYME ® is indicated for the treatment of: adult and pediatric patients with Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I) and patients with the Scheie form of MPS I who have moderate to severe symptoms. ALDURAZYME is a hydrolytic lysosomal glycosaminoglycan (GAG)-specific enzyme indicated for the treatment of adult and pediatric patients with Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I) and for the treatment of patients with the Scheie form of MPS I who have moderate to severe symptoms. ( 1 ) Limitations of Use: The risks and benefits of treating mildly affected patients with the Scheie form have not been established. ( 1 ) ALDURAZYME has not been evaluated for effects on the central nervous system manifestations of the disorder. ( 1 ) Limitations of Use The safety and effectiveness of treating mildly affected patients with the Scheie form have not been established. The effect of ALDURAZYME on central nervous system manifestations of the disorder has not been determined.
Showing 1-1 of 1
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances